Last reviewed · How we verify
NCT07321028: CRYO-IVT
Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001)
EARLY_PHASE1 trial testing Standard Laboratory Cryopreservation Procedure in Cellular Injury and Post-Cryogenic Recovery in 50 participants. Enrolling by invitation.
10 December 2066
Quick facts
| Lead sponsor | Truway Health, Inc. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 10 December 2025 |
| Primary completion | 10 December 2066 |
| Estimated completion | 10 December 2066 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Standard Laboratory Cryopreservation Procedure
- Enhanced Laboratory Cryopreservation Procedure
- Normothermic Cell Culture Control
Conditions studied
- Cellular Injury and Post-Cryogenic Recovery — all drugs for Cellular Injury and Post-Cryogenic Recovery →
- Cryogenic Cellular Stress — all drugs for Cryogenic Cellular Stress →
- Cold-Induced Cellular Injury — all drugs for Cold-Induced Cellular Injury →
- Thermal Injury Response — all drugs for Thermal Injury Response →
Sponsor
Truway Health, Inc. — full company profile →
Who can join
Eligibility, any sex, with Cellular Injury and Post-Cryogenic Recovery or Cryogenic Cellular Stress. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This laboratory-based study evaluates the effects of controlled cryogenic preservation on human cell samples using Truway Health's in-vitro cryo therapeutic methodology. The study analyzes post-thaw viability, functional recovery, and morphological integrity following exposure to different cryopreservation parameters. Findings will support optimization of cryogenic protocols intended for future translational, biobanking, and therapeutic applications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07321028
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Truway Health, Inc. trials
Trials by the same sponsor.
- NCT07472023 — Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss · EARLY_PHASE1 · enrolling by invitation
- NCT07382804 — Mobile Behavioral Activation Program With Wearable Sensors and Secure Activity Verification · NA · enrolling by invitation
- NCT07221565 — Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine · Phase 1, PHASE2 · enrolling by invitation
- NCT07217730 — Healthcare Integrity & Anti-Fraud Enforcement · enrolling by invitation
- NCT07214896 — Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings · Phase 2 · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07321028 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Truway Health, Inc.
- Last refreshed: 6 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07321028.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing